基本信息
浏览量:244
职业迁徙
个人简介
I am a physician-scientist who has established a human translational research group that fosters the development of both laboratory immunologists, and clinical translational researchers. Allogeneic hematopoietic cell transplantation (alloHCT) cures blood cancer via beneficial graft-v-tumor immunity. Our overall research goal is to augment GVT while preventing dertimental graft versus host disease (GVHD). The Miklos lab pioneered protein microarray technologies to disciiver clinically relevant allogeneic antibodies, especially those targeting H-Y antigens following sex mismatched transplantation. Our discovery that allogeneic HY antibodies develop in association with chronic GVHD revealed a critical B cell role in chronic GVHD pathogenesis and our clinical trials established cGVHD therapeutic benefits using anti-B cell drugs rituximab and ibrutinib. We developed high-throughput sequencing of the B and T cell immune receptor thereby enabling: 1) lymphoid disease quantification, 2) detailed B and T cell donor reconstitution kinetics, and 3) clonal analysis of antigen specific responses following allo-HCT.
Immunotherapy is revolutionizing cancer treatment and as the Stanford Clinical Cancer Cell Therapy program develops and evaluates the most promising cutting-edge cell therapies for cancer patients on a variety of clinical trials. Chimeric Antigen T Cell (CAR-T) therapy targets the patient's T lymphocytes to attack their cancer by infecting their own T cells to express chimeric antigen receptor (CAR) proteins that target and kill cancer cell expressing surface proteins. Thus far, the most successful CAR-T have targeted B cell antigen CD19, and ongoing trials are treating patients with relapsed/refractory Diffuse Large B Cell Lymphoma (DLBCL) using this CAR19 therapy.
Immunotherapy is revolutionizing cancer treatment and as the Stanford Clinical Cancer Cell Therapy program develops and evaluates the most promising cutting-edge cell therapies for cancer patients on a variety of clinical trials. Chimeric Antigen T Cell (CAR-T) therapy targets the patient's T lymphocytes to attack their cancer by infecting their own T cells to express chimeric antigen receptor (CAR) proteins that target and kill cancer cell expressing surface proteins. Thus far, the most successful CAR-T have targeted B cell antigen CD19, and ongoing trials are treating patients with relapsed/refractory Diffuse Large B Cell Lymphoma (DLBCL) using this CAR19 therapy.
研究兴趣
论文共 468 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Esther H Nie,Yi-Jiun Su,John H Baird, Neha Agarwal,Sushma Bharadwaj,Wen-Kai Weng, Melody Smith,Saurabh Dahiya,May H Han,Jeffrey E Dunn,Lucas B Kipp,David B Miklos,
Blood advancesno. 6 (2024): 1474-1486
Blood (2024)
Jay Spiegel,Jean S. Oak, Anmol Goyal, Scott Bornheimer, Allison Irvine,Rhine R. Shen,Katherine A. Kong,Sushma Bharadwaj,Wen-Kai Weng, Melody Smith,Matthew J. Frank,Saurabh Dahiya,
Transplantation and Cellular Therapyno. 2 (2024): S204
Everett Meyer, Anna Pavlova,Lori Muffly,Katherine Sutherland,Cameron Bader, Sushma Bharawaj,Saurabh Dahiya,Matthew Frank,Sally Arai,Laura Johnston,David Miklos,Andrew Rezvani,
crossref(2024)
Esther Nie, Yi-Jiun Su,John Baird, Neha Agarwal,Sushma Bharadwaj,Wen-Kai Weng,Saurabh Dahiya,Jeffrey Dunn,May Han,Lucas Kipp,David Miklos,Brian Scott,
Matthew A. Lunning,Hai‐lin Wang,Zhen‐Huan Hu, Frederick L. Locke,Tanya Siddiqi, Caron A. Jacobson,Sairah Ahmed,David B. Miklos,Yi Lin,Brian T. Hill,Armin Ghobadi,Sattva S. Neelapu,
American Journal of Hematology (2024)
Blood advances (2024)
Liora M. Schultz,Nikeshan Jeyakumar, Anne Marijn Kramer,Bita Sahaf, Hrishi Srinagesh,Parveen Shiraz, Neha Agarwal,Mark Hamilton,Courtney Erickson,Ashley Jacobs,Jennifer Moon,Christina Baggott,
Leukemiapp.1-6, (2024)
Haematologicano. 3 (2024): 777-786
Transplantation and Cellular Therapy (2024)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn